Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 13-23

  Tanaka, Tetsuji ^a   Toujima, Saori ^a   Utsunomiya, Tomoko ^a   Yukawa, Kazunori ^a   Umesaki, Naohiko ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticancer drug sensitivity; Immature teratoma; Karyotype; Ovary; Postoperative recurrence

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOMYCIN C; NEDAPLATIN; PACLITAXEL; PEPLEOMYCIN; PIRARUBICIN; SMOOTH MUSCLE ACTIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; CANCER CELL; CANCER GRADING; CANCER RECURRENCE; CASE REPORT; CELL CULTURE; CONTROLLED STUDY; DRUG SENSITIVITY; EXPERIMENTAL STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KARYOTYPE; NONHUMAN; NUDE MOUSE; OVARY TERATOMA; PERITONEUM CELL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; ADOLESCENT; ANIMAL; DRUG SCREENING; KARYOTYPING; MOUSE; OVARY TUMOR; PATHOLOGY; TERATOMA; TUMOR CELL LINE; TUMOR RECURRENCE;

ADOLESCENT; ANIMALS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; KARYOTYPING; MICE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TERATOMA;

EID: 49849084483     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.13     Document Type: Article

References (35)

1. Chang FH, Lai CH, Chu KK, Chang TC, Hsueh S and Hung IJ: Treatment of malignant germ cell tumors of the ovary. J Formos Med Assoc 93: 411-416, 1994.
2. Tseng CJ, Chou HH, Huang KG, Chang TC, Liang CC, Lai CH, Soong YK, Hsueh S and Pao CC: Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol 63: 364-370, 1996.
3. Kojs Z, Urbanski K, Mitus J, Reinfuss M, Pudelek J and Walasek T: Pure immature teratoma of the ovary: analysis of 22 cases. Eur J Gynaecol Oncol 18: 534-536, 1997.
4. Slayton RE, Hreshchyshyn MM, Silverberg SC, Shingleton HM, Park RC, DiSalia PJ and Blessing JA: Treatment of malignant ovarian germ cell tumors: response to vincristine, dactinomycin and cyclophosphamide (preliminary report). Cancer 42: 390-398, 1978.
5. Slayton RE, Park RC, Silverberg SG, Shingleton H, Creasman WT and Blessing JA: Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer 56: 243-248, 1985.
6. Gershenson DM, Copeland LJ, Kavanagh JJ, Cangir A, Del Junco G, Saul PB, Stringer CA, Freedman RS, Edwards CL and Wharton JT: Treatment of malignant nondysgerminomatous germ cell tumors of the ovary with vincristine, dactinomycin and cyclophosphamide. Cancer 56: 2756-2761, 1985.
7. Schneider J, Erasun F, Hervas JL, Acinas O and Gonzalez-Rodilla I: Normal pregnancy and delivery two years after adjuvant chemotherapy for grade III immature ovarian teratoma. Gynecol Oncol 29: 245-249, 1988.
8. Wong LC, Ngan HY and Ma HK: Primary treatment with vincristine, dactinomycin, and cyclophosphamide in nondysgerminomatous germ cell tumor of the ovary. Gynecol Oncol 34: 155-158, 1989.
9. Kosloske AM, Favara BE, Hays T, Major FJ and Bailey WC: Management of immature teratoma of the ovary in children by conservative resection and chemotherapy. J Pediatr Surg 11: 839-846, 1976.
10. Gershenson DM, Copeland LJ, del Junco G, Edwards CL, Wharton JT and Rutledge FN: Second-look laparotomy in the management of malignant germ cell tumors of the ovary. Obstet Gynecol 67: 789-793, 1986.
11. Carlson RW, Sikic BI, Turbow MM and Ballon SC: Combination cisplatin, vinblastine and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol 1: 645-651, 1983.
12. Kumar L, Bhargawa VL and Kumar S: Cisplatin, vinblastine and bleomycin in advanced and relapsed germ cell tumours of ovary. Asia Oceania J Obstet Gynaecol 19: 133-140, 1993.
13. Gershenson DM, Morris M, Cangir A, Kavanagh JJ, Stringer CA, Edwards CL, Silva EG and Wharton JT: Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin. J Clin Oncol 8: 715-720, 1990.
14. Lu KH and Gershenson DM: Update on the management of ovarian germ cell tumors. J Reprod Med 50: 417-425, 2005.
15. Warne GL, Fairley KF, Hobbs JB and Martin FI: Cyclophosphamide-induced ovarian failure. N Engl J Med 289: 1159-1162, 1973.
16. Koyama H, Wada T, Nishizawa Y, Iwanaga T and Aoki Y: Cyclophosphamide-induced ovarian failure and its therapeutic signifi-cance in patients with breast cancer. Cancer 39: 1403-1409, 1977.
17. Ataya K and Moghissi K: Chemotherapy-induced premature ovarian failure: mechanisms and prevention. Steroids 54: 607-626, 1989.
18. Choo YC, Chan SY, Wong LC and Ma HK: Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Cancer 55: 2348-2352, 1985.
19. Keilholz U, Korbling M, Fehrentz D, Bauer H and Hunstein W: Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer 64: 641-645, 1989.
20. Clark ST, Radford JA, Crowther D, Swindell R and Shalet SM: Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen. J Clin Oncol 13: 134-139, 1995.
21. Kikuchi Y, Momose E, Kizawa I, Ishida M, Sunaga H, Mukai K, Seki K and Kato K: Characterization of an established cell line from human immature teratoma of the ovary and effects of retinoic acid on cell proliferation. Cancer Res 44: 2952-2958, 1984.
22. Tanaka T, Nakajima S and Umesaki N: Cellular heterogeneity in long-term surviving cells isolated from eutopic endometrial, ovarian endometrioma and adenomyosis tissues. Oncol Rep 10: 1150-1160, 2003.
23. Gibas Z, Prout GR, Conolly JG, Pontes JE and Sandberg AA: Non-random chromosome changes in transitional cell carcinoma of the bladder. Cancer Res 44: 1257-1264, 1984.
24. Toshida MA, Ohyashiki K, Ochi H, Gibas Z, Pontes JE, Prout GR, Huben R and Sandberg AA: Cytogenetic studies of tumor tissue rom patients with nonfamilial renal cell carcinoma. Cancer Res 46: 2139-2147, 1986. 25 Yunis JJ: New chromosome techniques in the study of human neoplasia. Hum Pathol 12: 540-549, 1981.
25. Inoue M, Kyo S, Fujita M, Enomoto T and Kondoh G: Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 54: 3049-3053, 1994.
26. Postovsky S, Epelbaum M, Ben Itzhak O, Beck D and Ben Arush MW: Growing teratoma syndrome treated by interferon alpha-2beta: case report and literature review. Pediatr Hematol Oncol 21: 9-16, 2004.
27. Ihara T, Ohama K, Satoh H, Fujii T, Nomura K and Fujiwara A: Histologic grade and karyotype of immature teratoma of the ovary. Cancer 54: 2988-2994, 1984.
28. Ohama K, Nomura K, Okamoto E, Fukuda Y, Ihara T and Fujiwara A: Origin of immature teratoma of the ovary. Am J Obstet Gynecol 152: 896-900, 1985.
29. King ME, Micha JP, Allen SL, Mouradian JA and Chaganti RS: Immature teratoma of the ovary with predominant malignant retinal anlage component. A parthenogenically derived tumor. Am J Surg Pathol 9: 221-231, 1985.
30. Yang-Feng TL, Katz SN, Cacangiu ML and Schwartz PE: Cytogenetic analysis of ependymoma and teratoma of the ovary. Cancer Genet Cytogenet 35: 83-89, 1988.
31. King ME, DiGiovanni LM, Yung JF and Clarke-Pearson DL: Immature teratoma of the ovary grade 3, with karyotype analysis. Int J Gynecol Pathol 9: 178-184, 1990.
32. Gibas Z, Talerman A, Faruqi S, Carlson J and Noumoff J: Cytogenetic analysis of an immature teratoma of the ovary and its metastasis after chemotherapy-induced maturation. Int J Gynecol Pathol 12: 276-280, 1993.
33. Tanaka T, Umesaki N and Ogita S: Effects of shakuyaku-kanzoto on menopausal symptoms in an ovarian cancer patient treated with irinotecan HC1. J Trad Med 15: 456-457, 1998.
34. Tanaka T, Utsunomiya T, Utsunomiya H and Umesaki N: Irinotecan HC1, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal women. Oncol Rep 19: 1123-1133, 2008.
35. Utsunomiya T, Tanaka T, Utsunomiya H and Umesaki N: A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HC1, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int J Oncol 32: 991-1000, 2008.